use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
US5965126A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 25, 1996 |
| Grant date | Oct 12, 1999 |
| Priority date | — |
| Expiry date | Mar 25, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of treating neoplastic disease whereby gene therapy treatments are employed in combination with a chemotherapy regime. A combinational therapy with anti-neoplastic alkylating agents will optimize host tumor sensitivity to these agents used alone or in combination with O.sup.6 -benzylguanine (BG) or a similar compound or compounds. Hematopoietic cells are infected with a transgene expressing a mutant AGT protein exhibiting DNA repair activity while imparting resistance to BG or a related compound. Introduction of the transduced hematopoietic cell population expressing the mutant AGT protein into the patient in tandem with the chemotherapeutic regime will substantially reduce myelosuppression traditionally associated with the administration of these anti-neoplastic drugs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.